Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Antitumor activity

From: Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

Response evaluation

Intention-to-treat population (n=52)

Efficacy-evaluable population (n=48)

Objective response rate, n (%)

34 (65.4)

34 (70.8)

95% CI

50.9−78.0

55.9−83.0

Disease control rate, n (%)

47 (90.4)

47 (97.9)

95% CI

79.0−96.8

88.9−99.9

Best overall response, n (%, 95% CI)

 Complete response

2 (3.9, 0.5−13.2)

2 (4.2, 0.5−14.3)

 Partial response

32 (61.5, 47.0−74.7)

32 (66.7, 51.6−79.6)

 Stable disease

13 (25.0, 14.0−38.9)

13 (27.1, 15.3−41.8)

 Progressive disease

1 (1.9, 0.1−10.3)

1 (2.1, 0.1−11.1)

 Not evaluable

4 (7.7, 2.1−18.5)

-

  1. Data are shown as number (%) or number (%, 95% CI). Responses were assessed in accordance with RECIST version 1.1
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us